Thanks, Mike, and good morning to everyone. I want to echo Mike's remarks about our excitement at closing the merger with MRCC. With the additional capital from the merger as well as our new joint venture with Roth, we now have more size and scale as well as products to originate venture and growth loans to growing public and private companies. We believe this positions us well to continue growing our portfolio and NII over time. At the end of the quarter, our current portfolio stood at $696 million as we produced our second consecutive quarter of portfolio growth. In the first quarter, we funded 5 life science debt investments, including refinancing of an existing investment, totaling $120 million. We also made further progress in building our pipeline, including larger venture loan opportunities in our target sectors. One of those pipeline opportunities, Stellar Cyber closed in April. In Q1, we increased our committed backlog by $26 million from the end of Q4, which positions us well to further grow our portfolio in the quarters ahead. In Q2, we expect to further grow our portfolio, driven by our current pipeline. Along with Stellar Cyber, since the end of the quarter, we have been awarded 5 new venture loan transactions, representing $90 million in total commitments. It goes without saying that we will always be disciplined in originating and underwriting new loans. During the first quarter, we experienced 1 loan prepayment and refinancing totaling $63 million in prepaid principal. Our onboarding debt investment yield of 12% during the first quarter remained consistent with our historic levels. We expect to continue to generate strong onboarding yields with our current pipeline of opportunities, which we believe will generate strong net investment income over time. Our debt portfolio yield of 15.2% for the quarter was once again among the highest yielding debt portfolios in the BDC industry. Our ability to generate industry-leading yields continues to be a testament to our venture lending strategy and our execution of such strategy across various market cycles and interest rate environments. As of March 31, we held warrants, equity and other investments in 99 portfolio companies with a fair value of $50 million. Structuring investments with warrants and equity rights is a key component of our venture debt strategy and a potential generator of shareholder value. As mentioned, we ended the quarter with a committed and approved backlog of $180 million compared to $154 million at the end of the fourth quarter. We believe our pipeline of investment opportunities, combined with our committed backlog with most of our funding commitments subject to companies achieving certain key milestones provides a solid base to prudently grow our portfolio over time. As of quarter end, 88% of the fair value of our debt portfolio consisted of 3 and 4 rated debt investments, while 12% of the fair value of our portfolio was rated 2 or 1, which is a modest improvement from our levels at the end of the fourth quarter. We continue to collaborate with all of our portfolio companies and utilizing a variety of strategies to optimize returns and create future value. Turning to the venture capital environment. According to PitchBook, approximately $267 billion was invested in VC-backed companies in the first quarter, which by itself exceeded all full year totals for investment except for 2021 and 2025. However, this record performance was completely due to large investments in AI. In fact, the top 5 investments accounted for $196 billion of that amount. Venture capital dollars are flowing again. However, there is a significant bifurcation in the marketplace as only the companies at the very top are receiving the lion's share of capital. A similar story is playing out in the exit markets. While exit value of nearly $350 billion puts 2026 on pace to smash records by June, 72% of that value is due to SpaceX's acquisition of xAI. Still excluding that acquisition, exit value of $97 billion was the largest quarter since the fourth quarter of 2021, driven primarily by AI acquisitions. The IPO market, however, remains muted with only 15 VC-backed IPOs during the quarter. Given the current geopolitical and macro uncertainty, we believe the IPO market will remain somewhat muted in the near term. Nonetheless, we believe the limited life science IPO market creates more opportunities for venture loan originations as evidenced by our fundings in the quarter. On the tech side, though we see the IPO market is muted, we see considerable optimism for tech IPOs, while we continue to conduct deep due diligence, particularly in AI and defense technology to determine the best types of opportunities for future investments. We continue to believe that venture debt remains a compelling option for these high-quality companies to access additional capital. As we move through 2026, we are excited for the new horizon and have been hard at work in identifying and targeting larger venture loan opportunities for both private and small cap public companies given our substantially enhanced capacity profile. Additionally, we continue to work diligently on optimizing outcomes with respect to our current portfolio. We remain confident that we are on the right path to expand our portfolio over the longer term and continue to lead in the venture lending space. We expect this will lead to increased NII over time and ultimately, additional value for shareholders. With that, I will now turn the call over to our Chief Financial Officer, Dan Trolio.